Literature DB >> 25586870

"Targeted" consent for pragmatic clinical trials.

David Wendler1.   

Abstract

Research on interventions within the standard of care has enormous potential, yet it also raises several ethical and regulatory challenges. Perhaps the most important is determining what consent process is needed for these "pragmatic" clinical trials. Some argue that pragmatic clinical trials need to obtain in-depth research consent. This approach ensures that patients are informed, but may introduce substantial selection bias and disruption of clinical care. Others argue that trials limited to interventions within the standard of care do not need to obtain research consent at all. While this approach avoids the problems with in-depth consent, it results in patients not knowing whether they are in research. The present manuscript proposes a way to avoid both sets of concerns. It argues that consent for research needs to supplement appropriate consent for standard care only to the extent that the research differs from standard care. Hence, pragmatic trials designed to mirror clinical care can obtain consent with only minimal additions to consent for standard care. This conclusion suggests that it may be possible for many pragmatic trials to obtain consent that is ethically appropriate, satisfies research regulations, and does not introduce substantial selection bias or clinical disruption.

Entities:  

Mesh:

Year:  2015        PMID: 25586870      PMCID: PMC4395600          DOI: 10.1007/s11606-014-3169-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  12 in total

1.  What should research participants understand to understand they are participants in research?

Authors:  David Wendler; Christine Grady
Journal:  Bioethics       Date:  2008-05       Impact factor: 1.898

2.  Neural correlates of dueling affective reactions to win-win choices.

Authors:  Amitai Shenhav; Randy L Buckner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

3.  Determining minimal risk for comparative effectiveness research.

Authors:  Steven Joffe; Alan Wertheimer
Journal:  IRB       Date:  2014 May-Jun

4.  Informed consent for pragmatic trials--the integrated consent model.

Authors:  Scott Y H Kim; Franklin G Miller
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  Ethics and regulatory complexities for pragmatic clinical trials.

Authors:  Jeremy Sugarman; Robert M Califf
Journal:  JAMA       Date:  2014-06-18       Impact factor: 56.272

6.  Informed consent for comparative effectiveness trials.

Authors:  James R Anderson; Toby L Schonfeld
Journal:  N Engl J Med       Date:  2014-05-15       Impact factor: 91.245

7.  When choice is demotivating: can one desire too much of a good thing?

Authors:  S S Iyengar; M R Lepper
Journal:  J Pers Soc Psychol       Date:  2000-12

Review 8.  Hydrochlorothiazide versus chlorthalidone in the management of hypertension.

Authors:  Kimberly M Neff; James J Nawarskas
Journal:  Cardiol Rev       Date:  2010 Jan-Feb       Impact factor: 2.644

9.  Medical decision making in situations that offer multiple alternatives.

Authors:  D A Redelmeier; E Shafir
Journal:  JAMA       Date:  1995-01-25       Impact factor: 56.272

Review 10.  Outcomes of patients who participate in randomised controlled trials compared to similar patients receiving similar interventions who do not participate.

Authors:  G E Vist; K B Hagen; P J Devereaux; D Bryant; D T Kristoffersen; A D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more
  9 in total

Review 1.  Ethical Issues in Pragmatic Cluster-Randomized Trials in Dialysis Facilities.

Authors:  Cory E Goldstein; Charles Weijer; Monica Taljaard; Ahmed A Al-Jaishi; Erika Basile; Jamie Brehaut; Charles L Cook; Jeremy M Grimshaw; Eduardo Lacson; Craig Lindsay; Meg Jardine; Laura M Dember; Amit X Garg
Journal:  Am J Kidney Dis       Date:  2019-06-19       Impact factor: 8.860

2.  Pragmatic Randomized Trials Without Standard Informed Consent?: A National Survey.

Authors:  Rahul K Nayak; David Wendler; Franklin G Miller; Scott Y H Kim
Journal:  Ann Intern Med       Date:  2015-09-01       Impact factor: 25.391

3.  Targeted Consent for Research on Standard of Care Interventions in the Emergency Setting.

Authors:  David Wendler; Neal W Dickert; Robert Silbergleit; Scott Y H Kim; Jeremy Brown
Journal:  Crit Care Med       Date:  2017-01       Impact factor: 7.598

4.  Public Attitudes toward Consent When Research Is Integrated into Care-Any "Ought" from All the "Is"?

Authors:  Stephanie R Morain; Emily A Largent
Journal:  Hastings Cent Rep       Date:  2021-03       Impact factor: 2.683

5.  Stakeholders' views on the ethical challenges of pragmatic trials investigating pharmaceutical drugs.

Authors:  Shona Kalkman; Ghislaine J M W van Thiel; Diederick E Grobbee; Anna-Katharina Meinecke; Mira G P Zuidgeest; Johannes J M van Delden
Journal:  Trials       Date:  2016-08-22       Impact factor: 2.279

6.  Stakeholder perspectives regarding alternate approaches to informed consent for comparative effectiveness research.

Authors:  Stephanie R Morain; Ellen Tambor; Rachael Moloney; Nancy E Kass; Sean Tunis; Kristina Hallez; Ruth R Faden
Journal:  Learn Health Syst       Date:  2017-12-05

7.  Navigating ethical challenges of conducting randomized clinical trials on COVID-19.

Authors:  Dan Kabonge Kaye
Journal:  Philos Ethics Humanit Med       Date:  2022-01-28       Impact factor: 2.464

Review 8.  Alternative Consent Models in Pragmatic Palliative Care Clinical Trials.

Authors:  Joan G Carpenter; Connie Ulrich; Nancy Hodgson; Laura C Hanson; Mary Ersek
Journal:  J Pain Symptom Manage       Date:  2020-10-29       Impact factor: 5.576

Review 9.  Ethical issues in pragmatic randomized controlled trials: a review of the recent literature identifies gaps in ethical argumentation.

Authors:  Cory E Goldstein; Charles Weijer; Jamie C Brehaut; Dean A Fergusson; Jeremy M Grimshaw; Austin R Horn; Monica Taljaard
Journal:  BMC Med Ethics       Date:  2018-02-27       Impact factor: 2.652

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.